Jpmorgan Chase & CO Bridge Bio Pharma, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BBIO
# of Institutions
296Shares Held
176MCall Options Held
8.64MPut Options Held
2.84M-
Kohlberg Kravis Roberts & Co. L.P. New York, NY31.1MShares$783 Million45.4% of portfolio
-
Viking Global Investors LP25.1MShares$633 Million2.53% of portfolio
-
Vanguard Group Inc Valley Forge, PA14.1MShares$354 Million0.01% of portfolio
-
Black Rock Inc. New York, NY12.4MShares$314 Million0.01% of portfolio
-
Aisling Capital Management LP New York, NY6.07MShares$153 Million67.33% of portfolio
About BridgeBio Pharma, Inc.
- Ticker BBIO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 148,246,000
- Market Cap $3.74B
- Description
- BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...